Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology company advancing therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). This news hub provides investors and stakeholders with timely updates on PrimeC development, clinical trial progress, and strategic initiatives.
Access consolidated, verified information about NRSN's scientific advancements including Phase 2b trial results, regulatory submissions, and intellectual property milestones. Our repository features press releases covering clinical data analyses, partnership announcements, and biomarker research developments specific to ALS pathology.
Key updates include progress on PrimeC's extended-release formulation, patent grants for combination therapies, and FDA/Health Canada regulatory interactions. Bookmark this page for objective reporting on trial enrollment status, peer-reviewed publication alerts, and neurodegenerative treatment innovations.
NeuroSense Therapeutics has initiated a pharmacokinetic study for its lead drug candidate PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS). This study, conducted under an FDA-cleared protocol, enrolled the first healthy volunteer as of April 11, 2022. PrimeC combines the FDA-approved drugs ciprofloxacin and celecoxib to target mechanisms of ALS. The company anticipates reporting results by Q3 2022, which will inform a pivotal Phase III trial. PrimeC has received Orphan Drug Designation from both the FDA and EMA.
NeuroSense Therapeutics announced the grant of a key patent in Canada for its ALS drug, PrimeC, which combines FDA-approved drugs ciprofloxacin and celecoxib. The patent is valid through 2038 and complements similar patents issued in the U.S. and Australia. The company plans to initiate a Phase IIb trial in Q2 2022 to evaluate PrimeC's efficacy after a successful Phase IIa study. Concurrently, NeuroSense is collaborating with Massachusetts General Hospital on ALS biomarkers, with results expected in the same timeframe.
NeuroSense Therapeutics (Nasdaq: NRSN) announced new developments in its clinical program for lead drug candidate PrimeC targeting ALS. Two clinical studies are set to begin in Q2 2022, including a pharmacokinetic study and a Phase IIb multinational study, both aiming to enhance therapeutic effectiveness. The company is also expanding its intellectual property, with a key patent granted in the US and Australia. Upcoming data from studies on CogniC and StabiliC are anticipated in 2022, marking crucial milestones for NeuroSense's therapeutic pipeline.
NeuroSense Therapeutics Ltd. (NRSN) announced it has raised approximately $4 million through the exercise of warrants priced at $6 per share. This funding extends its cash runway through Q3 2023, coinciding with the planned Phase IIb study for PrimeC, targeting amyotrophic lateral sclerosis (ALS). PrimeC has previously met safety and efficacy endpoints in a Phase IIa study and has received Orphan Drug Designation from the FDA and EMA. ALS poses a significant healthcare burden affecting over 5,000 new patients annually in the U.S.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced FDA clearance to initiate a pharmacokinetic study of PrimeC, an oral formulation for ALS. PrimeC combines ciprofloxacin and celecoxib, targeting mechanisms of motor neuron degeneration. Having completed a successful Phase IIa study, NeuroSense is set to start a Phase IIb study in Q2 2022. The pharmacokinetic study will assess PrimeC's bioavailability in healthy subjects. The ALS treatment market is valued at $3 billion, with significant unmet needs identified, as ALS diagnoses are expected to increase by 24% by 2040.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced its participation in the 2022 Virtual Growth Conference on March 28-30, 2022. CEO Alon Ben-Noon will present during a fireside chat titled "NeuroSense – Novel Approach to Tackle ALS on Multiple Fronts" on March 30 at 09:30 AM EDT. The conference will feature various sectors, including biotech and healthcare, and will be hosted by Maxim Group LLC. NeuroSense focuses on developing treatments for neurodegenerative diseases, with promising results from its Phase 2a clinical study of PrimeC for ALS.
NeuroSense Therapeutics (Nasdaq: NRSN) announced the granting of a key patent in Australia for its lead ALS treatment, PrimeC, which combines ciprofloxacin and celecoxib. This patent complements the prior US patent and is valid until June 2038. The CEO highlighted the importance of this patent in enhancing their commercialization strategy. NeuroSense plans to start a Phase 2b study in May 2022 and has received Orphan Drug Designation in the US and Europe. Patent applications are also pending in various regions including Japan and Canada.
NeuroSense Therapeutics (Nasdaq: NRSN) announced that Dr. Shiran Zimri will present at the ASENT 2022 Annual Meeting on March 3, 2022, discussing PrimeC, a novel ALS therapy. PrimeC combines two FDA-approved drugs to target ALS, which currently has limited treatment options. The Phase 2a trial showed significant clinical improvements, and a Phase 2b study is planned for H1 2022. CEO Alon Ben-Noon emphasizes the importance of Dr. Zimri's presentation to ALS experts, aiming to establish PrimeC as a viable treatment.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced a presentation at the Aegis Capital Virtual Conference on February 25, 2022 at 8:30AM EST, part of a three-day event from February 23-25.
The conference will feature a company overview, and the slide deck will be available on their website. NeuroSense is focused on advanced therapies for neurodegenerative diseases like ALS and plans to start a Phase 2b study for its drug PrimeC in early 2022.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will present at the BIO CEO & Investor Conference on February 15, 2022, at 9:30 AM Eastern. The conference takes place from February 14 to 17 at the Marriott Marquis, New York City. CEO Alon Ben-Noon will discuss recent achievements and future plans, with the presentation available on NeuroSense's website. The clinical-stage biotechnology company focuses on treatments for neurodegenerative diseases like ALS and aims to begin Phase 2b trials for its drug PrimeC in mid-2022.
FAQ
What is the current stock price of Neurosense Therapeutics (NRSN)?
What is the market cap of Neurosense Therapeutics (NRSN)?
